Merck & Co Inc
NYSE: MRK
$96.31
-$2.05 (-2.1%)
Closing Price on November 15, 2024
MRK Articles
Pfizer, Merck, McDonald's, and Coca-Cola were the big losers Tuesday among the 30 Dow stocks.
Published:
Last Updated:
Merck released better-than-expected quarterly results and full-year guidance before the markets opened on Tuesday.
Published:
Last Updated:
Both Pfizer and Merck are scheduled to release their most recent quarterly results before the markets open on Tuesday. These are the two biggest companies in the pharma industry and they can set the...
Published:
Last Updated:
24/7 Wall St. has put together a preview of Apple, McDonald's, Pfizer and other Dow companies scheduled to report their quarterly results this week.
Published:
Last Updated:
The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Monday include Amazon.com, Caterpillar, Exxon Mobil, Honeywell, Lululemon Athletica, Merck, Petrobras and Under Armour.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Tuesday include Bristol-Myers Squibb, Chesapeake Energy, Coca-Cola, Dropbox, GrubHub, Merck, National Oilwell Varco, Netflix and...
Published:
Last Updated:
Lung cancer may have just met a new standard of care. On top of that, it would be considered a new standard as a first line of care in lung cancer and longer overall survival rates.
Published:
Last Updated:
UnitedHealth, Merck, Verizon, and Caterpillar led the Dow to a nice gain Monday.
Published:
Last Updated:
The March 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
Merck, Intel, JPMorgan Chase, and IBM led the Dow to a gain on Monday.
Published:
Last Updated:
Shares of Merck had a boost early Monday after the firm announced that its Phase 3 trial of Keytruda for the treatment of metastatic non-small cell lung cancer met its primary endpoint.
Published:
Last Updated:
Incyte saw its shares make a sharp left turn on Friday after the firm gave an update on its late-stage collaboration with Merck. NewLink Genetics felt the sting as well.
Published:
Last Updated:
Here is a 24/7 Wall St. calendar with a few of the biggest biotech and pharmaceutical companies expecting clinical trial and FDA updates in April.
Published:
Last Updated:
Merck and Walmart were among Wednesday's biggest gainers on the Dow while Intel and Cisco were among the big losers.
Published:
Last Updated: